采访诺贝尔奖得主大卫·巴尔的摩博士。

Q1 Medicine Pathogens and Immunity Pub Date : 2021-08-30 eCollection Date: 2021-01-01 DOI:10.20411/pai.v6i2.476
Michael M Lederman, Neil S Greenspan
{"title":"采访诺贝尔奖得主大卫·巴尔的摩博士。","authors":"Michael M Lederman, Neil S Greenspan","doi":"10.20411/pai.v6i2.476","DOIUrl":null,"url":null,"abstract":"In an online interview, Nobel Laureate David Baltimore, Ph.D., reflected on his contributions to biomedical science that have had a major influence on the fields of molecular biology, virology, cancer, and immunology. Dr. Baltimore is President Emeritus and Distinguished Professor of Biology at the California Institute of Technology. Among other notable works, he discovered the critical nuclear transcription factor NF Kappa B and the Rag1 and Rag2 proteins that rearrange adaptive immune cell receptors. \nHis career path, he says, evolved naturally, as math and science came easily to him. As a high school student, he participated in a summer program at the Jackson Lab in Bar Harbor, Maine, where he says he came away feeling that experimental biology was exciting and rewarding. \n“That's where I discovered that the frontiers of science, were not so distant; that I could actually make a discovery that nobody else in the world knew about,” he says.  \nAnd that he did. Independently, he and Howard Temin discovered the viral enzyme reverse transcriptase revising the canon of cellular information transfer. They published back-to-back papers in Nature demonstrating that this enzyme in virus particles could transcribe RNA to DNA. Both received a Nobel Prize for this work. \nIn reflecting on his early experience evaluating how to work with recombinant DNA and how we should scientifically and safely approach gain of function research, he says, “We have to be very honest with ourselves about what might hold danger, and we have to control our instinct … to do anything we can to generate progress and understanding of life. …At the same time, we don’t want to hold back progress, and so there is a balancing.” \nDr. Baltimore also discussed his optimism about vectored immunoprophylaxis as a strategy for prevention of HIV and his doubt that scalable strategies will be able to cure HIV. He also reflected on his philosophy for the training of young scientists and the successful training program that he developed at the Whitehead Institute.","PeriodicalId":36419,"journal":{"name":"Pathogens and Immunity","volume":" ","pages":"50-59"},"PeriodicalIF":0.0000,"publicationDate":"2021-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480539/pdf/","citationCount":"0","resultStr":"{\"title\":\"An interview with Nobel Laureate David Baltimore, PhD.\",\"authors\":\"Michael M Lederman, Neil S Greenspan\",\"doi\":\"10.20411/pai.v6i2.476\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In an online interview, Nobel Laureate David Baltimore, Ph.D., reflected on his contributions to biomedical science that have had a major influence on the fields of molecular biology, virology, cancer, and immunology. Dr. Baltimore is President Emeritus and Distinguished Professor of Biology at the California Institute of Technology. Among other notable works, he discovered the critical nuclear transcription factor NF Kappa B and the Rag1 and Rag2 proteins that rearrange adaptive immune cell receptors. \\nHis career path, he says, evolved naturally, as math and science came easily to him. As a high school student, he participated in a summer program at the Jackson Lab in Bar Harbor, Maine, where he says he came away feeling that experimental biology was exciting and rewarding. \\n“That's where I discovered that the frontiers of science, were not so distant; that I could actually make a discovery that nobody else in the world knew about,” he says.  \\nAnd that he did. Independently, he and Howard Temin discovered the viral enzyme reverse transcriptase revising the canon of cellular information transfer. They published back-to-back papers in Nature demonstrating that this enzyme in virus particles could transcribe RNA to DNA. Both received a Nobel Prize for this work. \\nIn reflecting on his early experience evaluating how to work with recombinant DNA and how we should scientifically and safely approach gain of function research, he says, “We have to be very honest with ourselves about what might hold danger, and we have to control our instinct … to do anything we can to generate progress and understanding of life. …At the same time, we don’t want to hold back progress, and so there is a balancing.” \\nDr. Baltimore also discussed his optimism about vectored immunoprophylaxis as a strategy for prevention of HIV and his doubt that scalable strategies will be able to cure HIV. He also reflected on his philosophy for the training of young scientists and the successful training program that he developed at the Whitehead Institute.\",\"PeriodicalId\":36419,\"journal\":{\"name\":\"Pathogens and Immunity\",\"volume\":\" \",\"pages\":\"50-59\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-08-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480539/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pathogens and Immunity\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.20411/pai.v6i2.476\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathogens and Immunity","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20411/pai.v6i2.476","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
An interview with Nobel Laureate David Baltimore, PhD.
In an online interview, Nobel Laureate David Baltimore, Ph.D., reflected on his contributions to biomedical science that have had a major influence on the fields of molecular biology, virology, cancer, and immunology. Dr. Baltimore is President Emeritus and Distinguished Professor of Biology at the California Institute of Technology. Among other notable works, he discovered the critical nuclear transcription factor NF Kappa B and the Rag1 and Rag2 proteins that rearrange adaptive immune cell receptors. His career path, he says, evolved naturally, as math and science came easily to him. As a high school student, he participated in a summer program at the Jackson Lab in Bar Harbor, Maine, where he says he came away feeling that experimental biology was exciting and rewarding. “That's where I discovered that the frontiers of science, were not so distant; that I could actually make a discovery that nobody else in the world knew about,” he says.  And that he did. Independently, he and Howard Temin discovered the viral enzyme reverse transcriptase revising the canon of cellular information transfer. They published back-to-back papers in Nature demonstrating that this enzyme in virus particles could transcribe RNA to DNA. Both received a Nobel Prize for this work. In reflecting on his early experience evaluating how to work with recombinant DNA and how we should scientifically and safely approach gain of function research, he says, “We have to be very honest with ourselves about what might hold danger, and we have to control our instinct … to do anything we can to generate progress and understanding of life. …At the same time, we don’t want to hold back progress, and so there is a balancing.” Dr. Baltimore also discussed his optimism about vectored immunoprophylaxis as a strategy for prevention of HIV and his doubt that scalable strategies will be able to cure HIV. He also reflected on his philosophy for the training of young scientists and the successful training program that he developed at the Whitehead Institute.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Pathogens and Immunity
Pathogens and Immunity Medicine-Infectious Diseases
CiteScore
10.60
自引率
0.00%
发文量
16
审稿时长
10 weeks
期刊最新文献
Historical Highlight: The Luria-Delbrück Fluctuation Test - A Study of the Nature of Bacterial Mutations Conferring Resistance to Infection by Bacteriophage. Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP3.3 From Approved Monoclonal Antibodies. Jonathan Yewdell Discusses Viral Immunology, Vaccine Development, Navigating a Scientific Career, and Offers Perspectives on Transforming Scientific Publishing and Research Education. Effect of Ceftaroline, Ceftazidime/Avibactam, Ceftolozane/Tazobactam, and Meropenem/Vaborbactam on Establishment of Colonization by Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice. People Living With HIV Have More Intact HIV DNA in Circulating CD4+ T Cells if They Have History of Pulmonary Tuberculosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1